Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

TLR3 signaling enhances the immunosuppressive properties of human periodontal ligament stem cells.

TRPV3 in skin cells causes inflammation and cell death.

Activating cannabinoid receptor 1 reduces certain keratin levels, potentially aiding psoriasis treatment.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Using DNase enzymes to break down harmful NETs could be a new treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.

A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.

Disrupting Stat3 in hair follicle stem cells greatly reduces skin tumor formation.

Deleting TNFα gene reduces skin cancer risk in certain mice.

CXCR2 in skin cells promotes tumor growth.

Mice with extra human KLK14 had hair and skin problems, including weaker cell bonds and inflammation, linked to Netherton syndrome.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.

The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Targeting PTEN can improve healing in venous leg ulcers.

Pannexin 3 helps skin and hair growth by controlling a protein called Epiprofin.

Cilostazol helps hair grow by making hair root cells grow faster and changing growth factor levels.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

Controlling transposable elements is crucial for successful tissue regeneration.

CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.

Activating TLR9 helps heal large wounds and regrow hair by involving a specific type of immune cell.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

Lack of TrkC receptor delays hair follicle development.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Disrupting Notch signaling in blood vessels increases scarring during wound healing in mice.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Genetic variants in specific genes cause a type of hair loss.